Crohn's fistula study looks back at MRI changes, not forward to new treatments

This study looked back at 52 Crohn's disease patients with anal fistulas who were treated with biotherapy (infliximab, adalimumab, ustekinumab, or vedolizumab). Researchers compared their MRI scans at the start of treatment and during follow-up to see how the fistulas changed over time. The goal was simply to describe these radiological changes, not to test a new drug or treatment.